Ellipticine

Ellipticine

Names
Preferred IUPAC name 5,11-Dimethyl-6H-pyrido[4,3-b]carbazole
Identifiers
CAS Number	519-23-3
3D model (JSmol)	Interactive image
ChEBI	CHEBI:4776
ChemSpider	3100
ECHA InfoCard	100.007.514
EC Number	208-264-0
KEGG	C09154
PubChem CID	3213
UNII	117VLW7484
CompTox Dashboard (EPA)	DTXSID30199855
InChI InChI=1S/C17H14N2/c1-10-14-9-18-8-7-12(14)11(2)17-16(10)13-5-3-4-6-15(13)19-17/h3-9,19H,1-2H3
SMILES CC1=C2C(=C(C3=C1C=CN=C3)C)C4=CC=CC=C4N2
Properties
Chemical formula	C17H14N2
Molar mass	246.313 g·mol−1
Appearance	Yellow crystalline powder [1]
Density	1.257±0.06 g/cm3 [2]
Melting point	316–318 °C (601–604 °F; 589–591 K) [2]
Solubility in water	Very low [3]
Hazards
Occupational safety and health (OHS/OSH):
Main hazards	toxic
GHS labelling:
Pictograms	[4]
Hazard statements	H301 [4]
Precautionary statements	P264, P270, P301+P310, P321, P330, P405, P501 [4]
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Ellipticine is a tetracyclic alkaloid first extracted from the tree species Ochrosia elliptica and Rauvolfia sandwicensis ^{[5] [6]} which inhibits the enzyme topoisomerase II via intercalative binding to DNA. ^[7]

Natural occurrence and synthesis

Ellipticine is an organic compound present in several trees within the genera Ochrosia , Rauvolfia , and Aspidosperma . ^[8] It was first isolated from Ochrosia elliptica Labill. , a flowering tree native to Australia and New Caledonia which gives the alkaloid its name, in 1959, ^[5] and synthesised by Robert Burns Woodward later the same year. ^[6]

Biological activity

Ellipticine is a known intercalator, capable of entering a DNA strand between base pairs. In its intercalated state, ellipticine binds strongly ^[9] and lies parallel to the base pairs, ^[10] increasing the superhelical density of the DNA. ^[11] Intercalated ellipticine binds directly to topoisomerase II, an enzyme involved in DNA replication, ^[12] inhibiting the enzyme and resulting in powerful antitumour activity. ^[10] In clinical trials, ellipticine derivatives have been observed to induce remission of tumour growth, but are not used for medical purposes due to their high toxicity; side effects include nausea and vomiting, hypertension, cramp, pronounced fatigue, mouth dryness, and mycosis of the tongue and oesophagus. ^[13]

Further DNA damage results from the formation of covalent DNA adducts following enzymatic activation of ellipticine by with cytochromes P450 and peroxidases, meaning that ellipticine is classified as a prodrug. ^[14]

References

1. Miller, R B; Dugar, S (1989). "A regiospecific total synthesis of ellipticine via nitrene insertion". Tetrahedron Letters. 30 (3): 297–300. doi:10.1016/S0040-4039(00)95184-0. ISSN   0040-4039.
2. "Ellipticine | 519-23-3". ChemicalBook. 2016. Retrieved 2017-05-30.
3. Sbai, M; Ait Lyazidi, S; Lerner, D A; del Castillo, B; Martin, M A (1996). "Use of micellar media for the fluorimetric determination of ellipticine in aqueous solutions". Journal of Pharmaceutical and Biomedical Analysis. 14 (8): 959–965. doi:10.1016/S0731-7085(96)01759-1. ISSN   0731-7085. PMID   8818001.
4. "Ellipticine | C17H14N2 - PubChem". PubChem. 2016. Retrieved 2017-05-30.
5. Goodwin, S; Smith, A F; Horning, E C (1959). "Alkaloids of Ochrosia elliptica Labill". Journal of the American Chemical Society. 81 (8): 1903–1908. Bibcode:1959JAChS..81.1903G. doi:10.1021/ja01517a031.
6. Woodward, R B; Iacobucci, G A; Hochstein, I A (1959). "The synthesis of ellipticine". Journal of the American Chemical Society. 81 (16): 4434–4435. Bibcode:1959JAChS..81.4434W. doi:10.1021/ja01525a085. ISSN   0002-7863.
7. Auclair, C (1987). "Multimodal action of antitumor agents on DNA: The ellipticine series". Archives of Biochemistry and Biophysics. 259 (1): 1–14. doi:10.1016/0003-9861(87)90463-2. ISSN   0003-9861. PMID   3318697.
8. Isah, T (2016). "Anticancer Alkaloids from Trees: Development into Drugs". Pharmacognosy Reviews. 10 (20): 90–99. doi: 10.4103/0973-7847.194047 . ISSN   0973-7847. PMC   5214563 . PMID   28082790.
9. Kohn, K W; Waring, M J; Glaubiger, D; Friedman, C A (1975). "Intercalative Binding of Ellipticine to DNA". Cancer Research. 35 (1): 71–76. ISSN   0008-5472. PMID   1109798.
10. Canals, A; Purciolas, M; Aymamí, J; Coll, M (2005). "The anticancer agent ellipticine unwinds DNA by intercalative binding in an orientation parallel to base pairs" (PDF). Acta Crystallographica D. 61 (7): 1009–1012. Bibcode:2005AcCrD..61.1009C. doi:10.1107/S0907444905015404. hdl: 10261/108793 . ISSN   0907-4449. PMID   15983425.
11. Chu, Y; Hsu, M T (1992). "Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation". Nucleic Acids Research. 20 (15): 4033–4038. doi:10.1093/nar/20.15.4033. ISSN   0305-1048. PMC   334084 . PMID   1324474.
12. Froelich-Ammon, S J; Patchan, M W; Osheroff, N; Thompson, R B (1995). "Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme–drug interactions by fluorescence spectroscopy". Journal of Biological Chemistry. 270 (25): 14998–15004. doi: 10.1074/jbc.270.25.14998 . ISSN   0021-9258. PMID   7797481.
13. Paoletti, C; Le Pecq, J B; Dat-Xuong, N; Juret, P; Garnier, H; Amiel, J L; Rouesse, J (1980). "Antitumor Activity, Pharmacology, and Toxicity of Ellipticines, Ellipticinium, and 9-Hydroxy Derivatives: Preliminary Clinical Trials of 2-Methyl-9-Hydroxy Ellipticinium (NSC 264-137)". Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research. Vol. 74. pp. 107–123. doi:10.1007/978-3-642-81488-4_15. ISBN   978-3-642-81490-7. ISSN   0080-0015. PMID   7003658.{{cite book}}: |journal= ignored (help)
14. Stiborová, M; Poljaková, J; Martínková, E; Ulrichová, J; Šimánek, V; Dvořák, Z; Frei, E (2012). "Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b₅". Toxicology. 302 (2–3): 233–241. Bibcode:2012Toxgy.302..233S. doi:10.1016/j.tox.2012.08.004. ISSN   0300-483X. PMID   22917556.